DT-6 is an effective TGF-β1 inhibitor. DT-6 inhibits M2 macrophage induced epithelial to mesencmal transition and invasive migration of cancer cells. DT-6 can be used for cancer diseases research.
DT-6 (0.1-50 μM, 0-18 h) reduces the protein level of TGF-β1 in THP-1, BV2, A549, MCF-7, U87, and HepG2 cells[1].DT-6 (50 μM, 24 h) decreases the secreted TGF-β1 in conditional medium (CM) of M2 macrophages[1].DT-6 (20 μM,50 μM, 24 h, 48 h) inhibits the inductive ability of M2 macrophages towards epithelial to mesencmal transition (EMT) and invasive migration of cancer cells through reducing TGF-β1 secretion[1].
References:
[1]. Feng Y, et al. Degradation of intracellular TGF-β1 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events. Chem Commun (Camb). 2020 Mar 5;56(19):2881-2884.